BTS 74,398 explained

BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor.[1] It was effective in animal models of Parkinson's disease,[2] [3] but was unsuccessful in human trials.[4]

Notes and References

  1. Lane EL, Cheetham S, Jenner P . Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors . The Journal of Pharmacology and Experimental Therapeutics . 312 . 3 . 1124–31 . March 2005 . 15542624 . 10.1124/jpet.104.076554 . 8208352 .
  2. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P . The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates . Movement Disorders . 19 . 1 . 15–21 . January 2004 . 14743355 . 10.1002/mds.10596 . 26120965 .
  3. Lane EL, Cheetham SC, Jenner P . Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours . The European Journal of Neuroscience . 21 . 1 . 179–86 . January 2005 . 15654855 . 10.1111/j.1460-9568.2004.03834.x . 22417785 .
  4. Lane EL, Cheetham S, Jenner P . Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398 . Journal of Neural Transmission . 2008 . 115 . 3 . 423–9 . 18250952 . 10.1007/s00702-007-0854-x . 195993 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BTS 74,398".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.